Kathleen D. Scott
CIK: 0001794284
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- Jun 16, 2026DRMA
Dermata Therapeutics, Inc.
Sale(S)Direct11 shares at avg. $1.19$13.091 - Jan 2, 2026DRMA
Dermata Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
2.5K shares- - Jan 2, 2026SPRY
ARS Pharmaceuticals, Inc.
Award(A)DirectStock option (right to buy)
240K shares- - Aug 21, 2025SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct12.5K shares at avg. $15.00$188K - Aug 21, 2025SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct12.5K shares at avg. $1.50$19K - May 20, 2025SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct50K shares at avg. $1.50$75K - May 20, 2025SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct50K shares at avg. $14.10$705K - Jan 13, 2025DRMA
Dermata Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
5K shares- - Jan 2, 2025SPRY
ARS Pharmaceuticals, Inc.
Award(A)DirectStock option (right to buy)
176.7K shares- - Dec 6, 2024NKGN
NKGen Biotech, Inc.
Award(A)DirectStock Option (right to buy)
300K shares- - Dec 6, 2024NKGN
NKGen Biotech, Inc.
Award(A)DirectStock Option (right to buy)
500K shares- - Oct 16, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct12.5K shares at avg. $16.00$200K - Oct 16, 2024SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct12.5K shares at avg. $1.50$19K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 16, 2026 |  DRMA Dermata Therapeutics, Inc. | Sale(S) | 11 | $1.19 | $13 | Direct |
| Jan 2, 2026 | DRMA Dermata Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 2,500 | - | - | Direct |
| Jan 2, 2026 |  SPRY ARS Pharmaceuticals, Inc. | Award(A) Stock option (right to buy) | 240,000 | - | - | Direct |
| Aug 21, 2025 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 12,500 | $15.00 | $187,500 | Direct |
| Aug 21, 2025 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 12,500 | $1.50 | $18,750 | Direct |
| May 20, 2025 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 50,000 | $1.50 | $75,000 | Direct |
| May 20, 2025 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 50,000 | $14.10 | $705,165 | Direct |
| Jan 13, 2025 | DRMA Dermata Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 5,000 | - | - | Direct |
| Jan 2, 2025 | SPRY ARS Pharmaceuticals, Inc. | Award(A) Stock option (right to buy) | 176,700 | - | - | Direct |
| Dec 6, 2024 |  NKGN NKGen Biotech, Inc. | Award(A) Stock Option (right to buy) | 300,000 | - | - | Direct |
| Dec 6, 2024 | NKGN NKGen Biotech, Inc. | Award(A) Stock Option (right to buy) | 500,000 | - | - | Direct |
| Oct 16, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 12,500 | $16.00 | $200,000 | Direct |
| Oct 16, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 12,500 | $1.50 | $18,750 | Direct |
1-13 of 13 transactions
About Scott Kathleen D.
Scott Kathleen D. (SEC CIK 0001794284) files insider reports with the SEC as Director of Dermata Therapeutics, Inc. (DRMA), Chief Financial Officer of ARS Pharmaceuticals, Inc. (SPRY) and Director of NKGen Biotech, Inc. (NKGN).
Signal8 holds 9 ownership filings by Scott Kathleen D., all Form 4s, filed between Oct 17, 2024 and Jun 16, 2026. Those filings report 13 transactions, from Oct 16, 2024 to Jun 16, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Scott Kathleen D.'s filings is in SAN DIEGO, CA.
Recent filings by Scott Kathleen D.
- Jun 16, 2026: Open-market sale of DRMA shares (Form 4, code S).
- Jan 2, 2026: Grant or award of DRMA derivative securities (Form 4, code A).
- Jan 2, 2026: Grant or award of SPRY derivative securities (Form 4, code A).
- Aug 21, 2025: Open-market sale of SPRY shares (Form 4, code S).
- Aug 21, 2025: Option exercise of SPRY shares (Form 4, code M).
Other insiders filing for Dermata Therapeutics, Inc. (DRMA)
- PROEHL GERALD T, PRESIDENT, CHAIRMAN, CEO
- Van Hoose Kyri K., SVP, CFO
- Bedoya-Toro Munera Maria E, SVP, Regulatory Affairs
- WIERENGA WENDELL, Director
- HALE DAVID F, Director
- Nardo Christopher J., Senior VP, CDO